REVENUE (Tables)

6 Months Ended

Apr. 30, 2023

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:



	Three Months Ended April 30,
	2023								2022
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	310	$	154	$	212	$	676	$	321	$	137	$	201	$	659
Europe	225		103		105		433		216		97		110		423
Asia Pacific	433		130		45		608		359		119		47		525
Total	$	968	$	387	$	362	$	1,717	$	896	$	353	$	358	$	1,607



	Six Months Ended April 30,
	2023								2022
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	642	$	308	$	413	$	1,363	$	638	$	269	$	389	$	1,296
Europe	484		201		204		889		468		195		211		874
Asia Pacific	875		259		87		1,221		766		248		97		1,111
Total	$	2,001	$	768	$	704	$	3,473	$	1,872	$	712	$	697	$	3,281

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2023		2022		2023		2022
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	612	$	589	$	1,251	$	1,191
Chemicals and Advanced Materials	378		335		784		708
Diagnostics and Clinical	250		241		489		484
Food	161		137		321		295
Academia and Government	159		146		305		287
Environmental and Forensics	157		159		323		316
Total	$	1,717	$	1,607	$	3,473	$	3,281

Revenue by Type
Instrumentation	$	689	$	646	$	1,448	$	1,337
Non-instrumentation and other	1,028		961		2,025		1,944
Total	$	1,717	$	1,607	$	3,473	$	3,281

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2023:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2022	$	557
Net revenue deferred in the period	370
Revenue recognized that was included in the contract liability balance at the beginning of the period	(299)
Change in deferrals from customer cash advances, net of revenue recognized	(21)

Currency translation and other adjustments	19
Ending balance as of April 30, 2023	$	626